Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins

被引:127
作者
Rauch, U
Osende, JI
Chesebro, JH
Fuster, V
Vorchheimer, DA
Harris, K
Harris, P
Sandler, DA
Fallon, JT
Jayaraman, S
Badimon, JJ
机构
[1] CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Cardiovasc Biol Res Lab, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA
关键词
statin; hyperlipidemia; thrombosis; endothelium; atherosclerosis;
D O I
10.1016/S0021-9150(00)00397-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cholesterol lowering involving different therapies improves the clinical outcome of patients. To define the underlying pathomechanism, we studied whether treatment with statins was associated with changes in blood thrombogenicity, endothelial dysfunction and soluble adhesion molecule levels. Fifty hypercholesterolemic patients were treated with pravastatin (40 mg/day, n = 24) or simvastatin (20 mg/day, n = 26). Lipid profile and blood thrombogenicity were assessed in all patients before and after 3 months of cholesterol reducing therapy. Blood thrombogenicity was assessed as thrombus formation, perfusing non-anticoagulated blood directly from the patients' vein through the Badimon perfusion chamber (shear rate 1690/s). Endothelial-dependent vasomotor response was tested by laser-Doppler flowmeter. Soluble adhesion molecule level were measured by ELISA. Total and LDL cholesterol were reduced ill the two treatment groups by statin therapy. Statin therapy was associated with a significant reduction in blood thrombogenicity and endothelium-dependent vasoresponse. No differences were observed between simvastatin or pravastatin treatment. Lipid lowering by statins had no effect on plasma levels of fibrinogen, sl-selectin, sP-selectin and sICAM-I antigen. Cholesterol lowering by both statins reduced the increased blood reactivity and endothelial dysfunction present under hypercholesterolemia. The multiple effects of lipid lowering therapy by statins may explain the benefits observed in recent epidemiological trials. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:181 / 189
页数:9
相关论文
共 41 条
[1]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[2]   Cholesterol lowering and coronary artery disease: mechanisms of risk reduction [J].
Archbold, RA ;
Timmis, AD .
HEART, 1998, 80 (06) :543-547
[3]   Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy [J].
Aviram, M ;
Hussein, O ;
Rosenblat, M ;
Schlezinger, S ;
Hayek, T ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (01) :39-45
[4]   PLATELET DEPOSITION AT HIGH SHEAR RATES IS ENHANCED BY HIGH PLASMA-CHOLESTEROL LEVELS - INVIVO STUDY IN THE RABBIT MODEL [J].
BADIMON, JJ ;
BADIMON, L ;
TURITTO, VT ;
FUSTER, V .
ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (02) :395-402
[5]  
BADIMON JJ, 1993, CIRCULATION, V87, P3
[6]  
BADIMON L, 1987, J LAB CLIN MED, V110, P706
[7]   HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages [J].
Bellosta, S ;
Via, D ;
Canavesi, M ;
Pfister, P ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) :1671-1678
[8]   No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia [J].
Broijersen, A ;
Eriksson, M ;
Leijd, B ;
Angelin, P ;
Hjemdahl, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (02) :273-278
[9]  
Bröijersén A, 1998, THROMB HAEMOSTASIS, V79, P268
[10]   Coronary risk factors and plaque morphology in men with coronary disease who died suddenly [J].
Burke, AP ;
Farb, A ;
Malcom, GT ;
Liang, YH ;
Smialek, J ;
Virmani, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) :1276-1282